阿比特龙联合布帕利塞(BKM120)或达托利塞(BEZ235)治疗去势抵抗性前列腺癌的Ib期剂量探索研究
这项Ib期研究评估泛PI3K抑制剂布帕利塞或双重PI3K/mTOR抑制剂达托利塞联合阿比特龙和泼尼松治疗去势抵抗性前列腺癌(CRPC)的最大耐受剂量和推荐扩展剂量。布帕利塞组在100mg每日一次时出现2例剂量限制性毒性,达托利塞组在200mg每日两次时5例患者出现9例剂量限制性毒性。基于药代动力学、安全性和有效性数据,不计划进一步研究两种联合方案。
要点
- 布帕利塞联合阿比特龙组25例患者,100mg每日一次时2例出现剂量限制性毒性。
- 达托利塞联合阿比特龙组18例患者,200mg每日两次时5例出现9例剂量限制性毒性。
- 布帕利塞联合阿比特龙未观察到客观缓解,PSA下降病例少。
核心结论
- 基于现有药代动力学、安全性和有效性数据评估,不计划进一步研究布帕利塞或达托利塞联合阿比特龙治疗去势抵抗性前列腺癌。
研究设计与样本
- Ib期剂量探索研究,纳入在阿比特龙治疗期间进展的去势抵抗性前列腺癌患者,接受布帕利塞或达托利塞递增剂量联合固定剂量阿比特龙(1000mg每日一次)和泼尼松(5mg每日两次)。
- 主要目标为确定布帕利塞或达托利塞联合阿比特龙的剂量限制性毒性、最大耐受剂量和/或推荐扩展剂量。
- 布帕利塞联合阿比特龙组25例患者,中位年龄67岁,ECOG体能状态0/1/2分别为7/17/1例。
- 达托利塞联合阿比特龙组18例患者,中位年龄71岁,ECOG体能状态0/1分别为6/12例。
主要发现
- 布帕利塞联合阿比特龙组在100mg每日一次时2例患者出现剂量限制性毒性(3级高血糖;2级乏力),此为探索的最高布帕利塞剂量。
- 布帕利塞联合阿比特龙组中位AUC0-24较首次人体研究中单药布帕利塞降低26%,中位Cmax降低48%。
- 布帕利塞联合阿比特龙组未观察到客观缓解,PSA下降病例少。
- 达托利塞联合阿比特龙组在首个剂量水平200mg每日两次时5例患者出现9例剂量限制性毒性(2级和3级口腔炎;3级高血糖;2级和3级腹泻;1级和2级发热、2级呕吐和2级寒战)。
关键数值与推荐
- 抗肿瘤活性按PCWG2标准评估,PSA下降30%定义为≥第12周时。
- 布帕利塞联合阿比特龙组在100mg每日一次时出现2例剂量限制性毒性。
- 达托利塞联合阿比特龙组在200mg每日两次时5例患者出现9例剂量限制性毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation in phosphatase and tensin homologue (PTEN)-deficient metastatic castration-resistant prostate cancer (CRPC) in preclinical models. This phase Ib study evaluated the pan-PI3K inhibitor buparlisib (BKM120) and the dual pan-PI3K/ mammalian target of rapamycin (mTOR) inhibitor dactolisib (BEZ235) in combination with abiraterone acetate (AA) in patients with CRPC. MATERIALS AND METHODS: Patients with CRPC who had progressed on AA therapy received escalating doses of either buparlisib or dactolisib, along with fixed doses of AA (1000 mg once daily (qd)) and prednisone (5 mg twice daily (bid)). The primary objective was to define the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of either buparlisib or dactolisib in combination with AA. Secondary objectives included safety, antitumour activity (Prostate Cancer Working Group 2 (PCWG2) criteria; 30% of prostate-specific antigen (PSA) decline at ≥week 12) and pharmacokinetic (PK) profile. RESULTS: In buparlisib + AA arm, 25 patients received buparlisib + AA (median age, 67 years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, respectively). At 100 mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycaemia; grade 2 asthenia), and this was the maximum buparlisib dose explored. Buparlisib + AA showed a 26% lower median area under the curve from time zero to 24°h (AUC0-24) and 48% lower median maximum serum concentration (Cmax) versus the single-agent buparlisib assessed in first-in-human study. No objective response and few PSA decreases were reported. In dactolisib + AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, respectively) received dactolisib + AA at the first dose level (200 mg bid). Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycaemia; grades 2& 3 diarrhoea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills). CONCLUSIONS: Based on the assessment of available pharmacokinetics, safety, and efficacy data, no further study is planned for either buparlisib or dactolisib in combination with AA in CRPC.
引用
- Massard C, Chi KN, Castellano D, et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer. 2017. PMID: 28282611. doi:10.1016/j.ejca.2017.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。